Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT1052230182
JPRN-jRCT1052230182
Not yet recruiting
Phase 4

Prospective Interventional Study on Ovarian Function Preservation by Endometrioma Ablation Using the Thulium YAG Laser

Kawahara Naoki0 sites10 target enrollmentFebruary 15, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsOvarian Endometriomaovarian endometrioma, infertilityD004715

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Ovarian Endometrioma
Sponsor
Kawahara Naoki
Enrollment
10
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 15, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Kawahara Naoki

Eligibility Criteria

Inclusion Criteria

  • •Patients with endometrioma who have been diagnosed as infertile, for whom surgery is indicated and for whom infertility treatment is covered by insurance.
  • •1\) Patients scheduled for abdominal or laparoscopic surgery
  • •2\) premenopausal women
  • •3\) Between 20 and 43 years of age at the time of consent.
  • •4\) The patient has the capacity to consent and is able to give written consent of her own free will.
  • •5\) ECOG\-PS1 or lower.
  • •(ECOG\-PS1 means that the patient is limited in strenuous activities, but can walk and perform light or sedentary tasks.)
  • •Patients who are eligible for surgery and whose postoperative infertility treatment is covered by insurance are selected.

Exclusion Criteria

  • •Exclude those that are known to affect serum AMH levels.
  • •1\) Those who have used sex hormones within 4 weeks prior to obtaining consent
  • •2\) Those with a history of surgery for endometriosis
  • •3\) Who have been diagnosed with a malignant tumor
  • •4\) Pregnant women or those who may be pregnant or breastfeeding
  • •5\) Patients who are judged by the principal investigator and subinvestigators to be unsuitable for this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 3
What is the most effective hormone treatment for women with premature ovarian insufficiency (POI), in both the short and long-term?
ISRCTN91141124niversity College London480
Active, not recruiting
Phase 2
A Phase II Study of Ovarian Function Suppression And ExemesTane with or without PalbocIclib in PreMenopausal Women with ER positive / HER-2 negative MetAstatic Breast Cancer (FATIMA)Metastatic Breast Cancer – OncologyNot applicableT51.2
LBCTR2019020181AMCI (Africa Middle East Cancer Intergroup)/Investigator Initiated Research160
Not yet recruiting
Phase 1
Clinical study on improving ovarian function of women with perimenopausal syndrome by Zishui Qinggan Lichong DecoctioPerimenopausal syndrome
ITMCTR2000002899The Third Affiliated Hospital of Beijing University of Chinese Medicine
Recruiting
Not Applicable
Observational pilot study on Diminished ovarian reserve in infertilityPregnancy, childbirth and the puerperium
KCT0002572Korea Institute of Oriental Medicine30
Active, not recruiting
Phase 1
Suppression of Ovarian Funktion Trial (SOFT)Histologically proven, resected breast cancer with ER and/or PgR positive tumorsMedDRA version: 19.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2004-000166-13-DEGBG Forschungs GmbH3,000